Altre lingue Shionogi & Co., Ltd.

Azioni

4507

JP3347200002

Mercato chiuso - Japan Exchange Altri mercati azionari 08:34:42 19/04/2024			Variaz. 5gg	Var. 1 gen.
7.114 ^JPY	-0,45%		-3,64%	+4,65%

29/03	Shionogi completa il riacquisto di azioni fino a 75 miliardi di yen	MT
07/03	Il trattamento iniettabile contro l'HIV dell'unità GSK ViiV Healthcare mostra un'"efficacia superiore" in uno studio di fase avanzata	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Shionogi & Co., Ltd. - Notice Regarding Completion of Cancellation of Treasury Shares	15:23
ESCMID Global 2024, Shionogi presents real-world data demonstrating efficacy of Fetcroja, Fetroja in critically ill patients with certain difficult-to-treat bacterial infections	15:22
Shionogi & Co Completes Cancellation of 10.84 Million Treasury Shares	14:11
Shionogi - The European Commission Grants Orphan Medicinal Product Designation for Zatolmilast, a Potential First-In-Class Treatment Being Investigated for Fragile X Syndrome	12/04
Shionogi Completes Up to 75 Billion Yen Share Buyback	29/03
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023.	28/03
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million.	22/03
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd.	21/03
Shionogi & Co., Ltd. - Recognized as One of the Highest-Ranking Companies on the Supplier Engagement Rating by CDP for the Fourth Consecutive Year	08/03
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial	07/03
Shionogi & Co., Ltd. - Notice Regarding the Status of Acquisition of Own Shares	06/03
Shionogi Announces Xocova Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	06/03
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen	06/03
ViiV Healthcare presents phase I clinical trial findings of a cabotegravir long-acting injectable investigational formulation allowing at least four months between doses \| GSK	05/03
GSK says ViiV's cabotegravir study supports longer HIV dose interval	05/03
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir	05/03
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection	05/03
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs	04/03
GSK's new HIV drug formula could support longer dosing intervals (March 4)	04/03
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval	04/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Shionogi & Co., Ltd.

Azioni

4507

JP3347200002

Altre lingue

Filtri